Skip to main content

Table 2 Laboratory examination of 288 patients with mercury poisoning

From: Epidemiology, clinical presentation, treatment, and follow‐up of chronic mercury poisoning in China: a retrospective analysis

Laboratory examination Subgroup Value   Statistic P
Blood mercury content a,medain(IQR),µg/L   9.35 (4.20 to 21.00) I Vs II Vs III 10.77 0.005
  Non-complication, I 8.20 (3.60 to 20.60) III Vs II 5.26 0.022
  Nephrotic syndromed, II 16.70 (7.80 to 37.80) II Vs I 10.47 0.001
  Peripheral nerve injuryd, III 10.20 (5.20 to 17.20) III Vs I 0.35 0.554
Urine mercury content a,medain(IQR),µg/L   13.50 (5.10 to 29.60) I Vs II Vs III 4.68 0.096
  Non-complication, I 13.25 (4.9 to 29.1) III Vs II 4.18 0.041
  Nephrotic syndrome, II 20.9 (8.3 to 37.8) II Vs I 3.17 0.075
  Peripheral nerve injury, III 9.5 (4.9 to 20) III Vs I 0.93 0.335
Creatinine,medain(IQR),µmol/L   56 (49 to 66)    
UMCa,medain(IQR),µmol/molb   128.57 (40.35 to 277.22) I Vs II Vs III 3.32 0.19
  Non-complication, I 125.18 (37.68 to 269.84) III Vs II 2.63 0.105
  Nephrotic syndrome, II 205.38 (70.34 to 411.36) II Vs I 2.89 0.089
  Peripheral nerve injury, III 221.95 (93.51 to 472.06) III Vs I 0.11 0.746
24-h urinary protein, median (IQR), g/24 h   0.42 (0.26 to 2.75)    
Renal biopsyb, n(%)c   39 (13.5 %)   24.10 < 0.001
  MN 20 (51.3 %)    
  MCN 14 (35.9 %)    
  MSPGN 3 (7.7 %)    
  FSGS 2 (5.1 %)    
EMGb, n(%)   39 (13.5 %)   6.79 0.036
  Neuropathy 33    
  Myopathy 1    
  FW 5    
  1. EMG electromyography, FSGS focal segmental glomerulosclerosis, FW F-wave, IQR interquartile range, MCN minimal-change nephropathy, MN membranous nephropathy, MSPGN mesangial proliferative glomerulonephritis, UMC urinary mercury/creatinine
  2. aOne-way analysis of variance by ranks (Kruskal-Wallis Test)
  3. bχ2 test
  4. cSubgroup's constituent ratio
  5. dNephrotic syndrome's diagnosis was established by renal biopsy and nerve injury's diagnosis was established by EMG